Isoquinoline compounds and their use in treating AhR imbalance
US11267788B2 · kind B2 · utility
0Cited by
5References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 27, 2021 |
| Grant date | Mar 8, 2022 |
| Priority date | — |
| Expiry date | May 27, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D217/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to novel compounds of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof. Pharmaceutical compositions comprising a compound of Formula (I), or a pharmaceutically acceptable salt, solvate or hydrate thereof, are also described. The invention is also directed to use of the compounds of Formula (I) for treating a condition in a mammal associated with AhR imbalance, such as an inflammatory disease or disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.